(Q34354430)

1 August 2017

title

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence (English)

1 reference

1 August 2017

1 reference

4

Ethan Basch

1 reference

1 August 2017

Timothy J Wilt

1

1 reference

1 August 2017

Peter T Scardino

series ordinal

2

1 reference

1 August 2017

Sigrid V Carlsson

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

4 March 2014

1 reference

Journal of the National Cancer Institute

1 August 2017

published in

1 reference

1 August 2017

volume

106

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

dju010

1 reference

1 August 2017

cites work

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Early detection of prostate cancer: AUA Guideline

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate specific antigen best practice statement: 2009 update

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

The benefits and harms of breast cancer screening: an independent review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Quality-of-life effects of prostate-specific antigen screening.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Radical prostatectomy versus observation for localized prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Bridging the gap: moving predictive and prognostic assays from research to clinical use

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate-cancer mortality at 11 years of follow-up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Risk-based prostate cancer screening.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Baseline prostate-specific antigen testing at a young age.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Outcomes of active surveillance for men with intermediate-risk prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Time trends and local variation in primary treatment of localized prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Screening for breast cancer with mammography

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Screening and prostate-cancer mortality in a randomized European study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Mortality results from a randomized prostate-cancer screening trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be diffic

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

6 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200071

Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet

27 October 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU010

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

21 January 2018

1 reference

12 December 2020

One man at a time--resolving the PSA controversy

1 reference

12 December 2020

Screening: simple messages ... sometimes

1 reference

12 December 2020

A piece of my mind. Making the call

1 reference

12 December 2020

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJU010

1 reference

1 August 2017

1 reference

1 August 2017

1 reference